合成目标产物 3,5-Bis(Trifluoromethyl)Phenylacetonitrile 主要起始原料 3,5-Bis(Trifluoromethyl)Chlorobenzene And Cyanoacetic Acid
328-70-1 = 85068-32-2 反应条件:1.1 Reagents: Lithium Chloride Catalysts: Bis(1,5-Cyclooctadiene)Nickel,2-(1H-Imidazol-2-Yl)Pyridine,2,4,5,6-Tetra(9H-Carbazol-9-Yl)Isophthalonitrile Solvents: Dimethyl Sulfoxide; 16 H,55 °C 标题:Photoinduced Nickel-Catalyzed Demethylative Cyanation And Decarboxylative Cyanomethylation Of Aryl Halides 作者:Lee,Shao-Chi; Zhu,Chen; Huang,Kun; Bau,Jeremy A.; Jia,Jiaqi; Et Al 参考文献:Acs Catalysis 日期:2023 卷标:13(24) 页码:16279-16285
在 甲醇体系中,化学反应生成 3,5-双(三氟甲基)苯乙腈 参考文献:Carbanion Reactivity; Kinetics Of The Reactions Of Benzyl Cyanide Anions With Aromatic Nitro-Compounds 标题:Carbanion Reactivity; Kinetics Of The Reactions Of Benzyl Cyanide Anions With Aromatic Nitro-Compounds 摘要:Rate And Equilibrium Measurements Are Reported For The Reactions In Methanol Of Carbanions Derived From 12 Ring-Substituted Benzyl Cyanides With 1,3,5-Trinitrobenzene To Give Sigma-Adducts. Some Data For Reaction Of The Carbanions With 4-Nitrobenzofuroxan Were Also Measured. With Increasing Carbanion Reactivity,Rate Constants Approach A Limit Of Just Below 10(9) Dm(3) Mol(-1) S(-1). Intrinsic Reactivities Of Carbanions In Sigma-Adduct Forming Transfer Reactions Are Compared. DOI:10.1039/p29950000443
专利号:US-9428490-B2 优先权日:2011-07-29 标 题 :Nuclear transport modulators and uses thereof 发明人:SANDANAYAKA VINCENT P; SHACHAM SHARON; KAUFFMAN MICHAEL; SHECHTER SHARON; MCCAULEY DILARA; LANDESMAN YOSEF; SENAPEDIS WILLIAM; SAINT-MARTIN JEAN-RICHARD 权利人:SANDANAYAKA VINCENT P; SHACHAM SHARON; KAUFFMAN MICHAEL; SHECHTER SHARON; MCCAULEY DILARA; LANDESMAN YOSEF; SENAPEDIS WILLIAM; SAINT-MARTIN JEAN-RICHARD; KARYOPHARM THERAPEUTICS INC 摘要:The invention generally relates to nuclear transport modulators, e.g CRM1 inhibitors, and more particularly to a compound represented by formula (I): or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula (I), or a pharmaceutically acceptable salt or composition thereof, e.g, in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.